Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Psychedelic healing...anyone see the Lisa Ling show? I dvred because i'm out of town but xfinity wont let me watch it away from my own wifi.
Buy ARIA...look at that 13/20!
So how does an open label extension of a double blind placebo controlled trial work without unblinding? Only way is for all patients to cross over to drug.
From today's Prana response:
Nice volume today
Only this:
MLV & Co. analyst George Zavoico said the company is making "good progress" and the delay happened because Prana found some inconsistencies and transcription errors between its database and reports in the study. He said those types of errors are not unusual even though Prana found more of them than it expected. Zavoico said he expect the study to succeed and maintained a "Buy" rating with a price target of $6 per share.
Good news is there are now 12 patient being dosed open label. And the share price is recovering.
I added about 3200 a few minutes ago.
Pran is a real momentum stock now. Shares climbing stepwise, flag after flag. This next flag measures to $9.50. If they are patient with the shelf they can get $8+ on the next PIPE... Even before the Huntington's data is released.
$1.70 ancient history...$34? :)
But seriously, if you want to say there's a two year cup and handle fro .80 to 2.20 we should be on the way to $3.80
That was me. You're welcome!
Pbth shares were about $5.70 when the news broke. Opko shares are now $9.19. That's good sex!
Pran: this author is going to have to publish another addendum... The Huntington trial reports in October, not the Alzheimer's trial.
http://www.fool.com/investing/general/2013/08/23/the-past-present-and-future-of-alzheimers-treatmen.aspx
"Open label" is by far the most important development. Patients on placebo will now get drug, and if it works, will start to show improvement.
PROLOR Biotech to Present Positive Results From Preclinical Studies of Long-Acting Clotting Factor VIIa-CTP at ISTH 2013
--New Data Show a Simple Subcutaneous Injection of Factor VIIa-CTP Could Potentially Replace Current Therapies Administered Via Infusion--
Press Release: PROLOR Biotech, Inc. – Wed, Jul 3, 2013 7:30 AM EDT
Email
RecommendTweet
Print
RELATED QUOTES
Symbol Price Change
PBTH 6.37
AMSTERDAM and NES-ZIONA, Israel, July 3, 2013 /PRNewswire/ -- PROLOR Biotech, Inc. (NYSE MKT: PBTH), today announced that the company will present new results from preclinical studies of its long-acting clotting factor VIIa (Factor VIIa-CTP), a next-generation investigational therapy in advanced preclinical development for the potential treatment of hemophilia. The data provide further evidence that Factor VIIa-CTP has the potential to be administered by subcutaneous (SC) injection as well as intravenously (IV), which would facilitate its prophylactic use by patients on an ongoing basis. The study results will be discussed in an oral presentation at the XXIV Congress of the International Society of Hemostasis and Thrombosis (ISTH).
Currently available commercial factor VIIa must be administered through IV infusion, which can be onerous for patients. This limits its use for prophylactic treatment and can require frequent administrations if patients are treated only "on demand" when a bleeding episode occurs.
The new preclinical results being presented at the ISTH Congress further confirm the efficacy of PROLOR's long-acting Factor VIIa-CTP and show that it has the potential to be administered using a simple SC injection. The combination of a long-acting product coupled with the ability to be administered by SC injection could change the way that factor VIIa is used, potentially allowing individuals with hemophilia to self-administer the drug at home on a prophylactic basis, improving their quality of life and potentially reducing the need for on-demand treatment of bleeding episodes.
Dr. Abraham Havron, CEO of PROLOR, commented, "We have previously presented data in animal models of hemophilia showing that Factor VIIa-CTP demonstrated long-acting properties compared to commercially available factor VIIa. These new data reflect our extensive recent work confirming those data and also assessing the potential of hGH-CTP to be administered by SC injection, which could be transformative for some hemophilia patients. Based on these exciting results, we expect to initiate two independent clinical programs for Factor VIIa-CTP in 2014—one for on-demand and prophylactic treatment of hemophilia using the IV route and a second for prophylactic treatment using the SC route."
The data will be presented by Dr. Gili Hart, Vice President, Pre-Clinical Development and Clinical Pharmacology at PROLOR and head of the company's long-acting clotting factors program. Dr. Hart's presentation, "A long-acting FVIIa-CTP proposing an improved prophylactic and on-demand treatment for hemophilic patients following SC and IV administration - evaluation in animal models," will be presented on July 4, 2013, at 9:15 am local time....
I don't see how frost destroyed shareholder value in pbth... It was trading less than $1 before up listing.
Strong cup and handle at 52 week high resistance... Should have a mean head of steam to get throug the 2.40-2.80 zone
Nope... Just a cup and handle with a $2.30 target
A great start again today... Should test $1.70 quickly if the volume holds.
Nice volume today! Should be an interesting afternoon.
I like that the daily 50sma has started to curl upwards.... Bottomed dec27th of so.
Nice day today...volume much stronger, RSI crossed to the power zone, and closed above the 50sma. Wouldn't be surprising if it tested below the 50sma a few times this week. If it does, expect high volume buys to push it back up.
Did I miss the pr announcing the earnings date? To me it is a suprise to see it is 8:30 today.
Oops, was trying to reply to both of you at the same time. Thanks!
Very funny techisbest!
See how many billions in market cap Lilly gained running into its phase III data reporting and add that to prana's tiny market cap... Staggering... The speculators are only now knocking on prana's door.
Pran stretching legs.
Is there anything on the ballots for the elections in other states? Here in MA w'ere voting for medical marijuana. Last time it was decriminalized in the state down to a $100 fine for possession of up to an ounce.
BLRX still says their MOA is to block virus induced autophagy....
http://finance.yahoo.com/news/biolinerx-announces-successful-completion-pre-110200108.html
BL-8020's mechanism of action involves the inhibition of HCV-induced autophagy in the host cells. Autophagy is a mechanism by which cells degrade damaged or unnecessary cellular components, including invading viruses. However, HCV has found a way to take advantage of this mechanism in order to replicate inside the cell. By inhibiting this mechanism, BL-8020 reduces the ability of HCV to replicate.
lots of bullish engulfing action in the last two weeks.
The Molecular Basis of Memory.
(sounds very much like the way electrons are stored in insulated compartments on a silicon chip)
ACS Chem Neurosci. 2012 Aug 15;3(8):633-642.
Marx G, Gilon C.
MX Biotech Ltd. , Jerusalem, Israel.
Abstract
We propose a tripartite biochemical mechanism for memory. Three physiologic components are involved, namely, the neuron (individual and circuit), the surrounding neural extracellular matrix, and the various trace metals distributed within the matrix. The binding of a metal cation affects a corresponding nanostructure (shrinking, twisting, expansion) and dielectric sensibility of the chelating node (address) within the matrix lattice, sensed by the neuron. The neural extracellular matrix serves as an electro-elastic lattice, wherein neurons manipulate multiple trace metals (n 10) to encode, store, and decode coginive information. The proposed mechanism explains brains low energy requirements and high rates of storage capacity described in multiples of Avogadro number (N(A) = 6 × 10(23)). Supportive evidence correlates memory loss to trace metal toxicity or deficiency, or breakdown in the delivery/transport of metals to the matrix, or its degradation. Inherited diseases revolving around dysfunctional trace metal metabolism and memory dysfunction, include Alzheimer's disease (Al, Zn, Fe), Wilson's disease (Cu), thalassemia (Fe), and autism (metallothionein). The tripartite mechanism points to the electro-elastic interactions of neurons with trace metals distributed within the neural extracellular matrix, as the molecular underpinning of "synaptic plasticity" affecting short-term memory, long-term memory, and forgetting.
Shouldn't we all hope so?
34% reduction in DECLINE doesn't sound good.
The one at 28 is scarier... Lower volume. The 29 gap had volume on the gap and big volume on the retest.
PRAN second round of action? 20 sma held strongly...13/20kiss... Up %16 in Australia last night.
Dude, nice to see you back on this board. Have you re-established a position?
I'm rather pleased the price held strongly. The open was very strong... Probably speculators thinking something would be announced at the webcast because it promptly dropped afterwards. I've never seen a stock spend most of the day green on good volume after a pipe... So much higher than the pipe price. They can't sell in another pipe this year without shareholder approval, and they likely won't be selling any more ATM shares, so the good news is they are well funded for the year and the spigot is turned off, so the price should advance with further anticipation.
Prana Announces A$6.0 Million Capital Raising
Press Release: Prana Biotechnology – 8 minutes ago
Companies:
Prana Biotechnology Ltd.Prana Biotechnology Ltd.
RELATED QUOTES
Symbol Price Change
PRAN 2.37
MELBOURNE, AUSTRALIA--(Marketwire - Oct 1, 2012) - Prana Biotechnology Limited ( NASDAQ : PRAN ) ( ASX : PBT ) today announced that it has raised A$6.0 million (approx.) through a placement of 32,500,000 ordinary fully paid shares (equivalent to 3.25 million NASDAQ listed ADRs) at a price of A$0.185 per share. The placement attracted strong demand even though the amount raised was restricted by the number of shares which could be issued by the Company under ASX listing rule 7.1, thereby not requiring a separate meeting of shareholders.
The placement was subscribed by a range of leading Australian institutional investors within the healthcare sector in Australia, as well as several High Net Worth Investors. The placement was managed by JM Financial Group Limited, based in Melbourne.
The capital was raised in order to support Prana's two ongoing Phase 2 clinical trials, the IMAGINE trial and Reach2HD trial, testing the effects of its lead drug candidate, PBT2, in Alzheimer's and Huntington disease patients, respectively. Results are anticipated to be reported in 2H13.
"The funds raised by Prana via this placement, reflect strong commitment to Prana's clinical development programmes and the commercial opportunity this provides. The endorsement of and participation by some of Australia's leading healthcare investors is very welcome," said Geoffrey Kempler, Prana's Executive Chairman.
Prana management and scientific advisors are on a roadshow this week in Melbourne, New York, Boston and London, updating the investment community on Prana's progress.
About Prana Biotechnology Limited
Prana Biotechnology was established to commercialize research into age-related neurodegenerative disorders. The Company was incorporated in 1997 and listed on the Australian Securities Exchange in March 2000 and listed on NASDAQ in September 2002. Researchers at prominent international institutions including The University of Melbourne, The Mental Health Research Institute (Melbourne) and Massachusetts General Hospital, a teaching hospital of Harvard Medical School, contributed to the discovery of Prana's technology.
For further information please visit the Company's web site at www.pranabio.com.
Forward Looking Statements
This press release contains "forward-looking statements" within the meaning of section 27A of the Securities Act of 1933 and section 21E of the Securities Exchange Act of 1934. The Company has tried to identify such forward-looking statements by use of such words as "expects," "intends," "hopes," "anticipates," "believes," "could," "may," "evidences" and "estimates," and other similar expressions, but these words are not the exclusive means of identifying such statements. Such statements include, but are not limited to any statements relating to the Company's drug development program, including, but not limited to the initiation, progress and outcomes of clinical trials of the Company's drug development program, including, but not limited to, PBT2, and any other statements that are not historical facts. Such statements involve risks and uncertainties, including, but not limited to, those risks and uncertainties relating to the difficulties or delays in financing, development, testing, regulatory approval, production and marketing of the Company's drug components, including, but not limited to, PBT2, the ability of the Company to procure additional future sources of financing, unexpected adverse side effects or inadequate therapeutic efficacy of the Company's drug compounds, including, but not limited to, PBT2, that could slow or prevent products coming to market, the uncertainty of patent protection for the Company's intellectual property or trade secrets, including, but not limited to, the intellectual property relating to PBT2, and other risks detailed from time to time in the filings the Company makes with Securities and Exchange Commission including its annual reports on Form 20-F and its reports on Form 6-K. Such statements are based on management's current expectations, but actual results may differ materially due to various factions including those risks and uncertainties mentioned or referred to in this press release. Accordingly, you should not rely on those forward-looking statements as a
PRAN trading halt on asx
Finally they got rid of those crooked purple bins.